Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan may spot hidden heart harm in childhood cancer survivors

NCT ID NCT01671696

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 80 childhood cancer survivors who had received high doses of anthracycline chemotherapy. Researchers used cardiac MRI and blood tests to find early signs of heart damage that standard tests might miss. The goal was to see if these advanced methods could detect hidden heart problems before symptoms appear, potentially allowing earlier treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to detect heart damage early in childhood cancer survivors, potentially preventing heart failure.
What could go wrong
This is an observational study, not a treatment trial. The findings may not lead to new therapies, and the small size (80 participants) limits how widely results can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Nov 2011

Finished

Oct 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Survivors of childhood cancer who were treated with anthracyclines and are greater than 2 years from their last cycle of chemotherapy

Ages

9 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

5.1 A. Subject Inclusion Criteria * Childhood cancer survivors from the late effect clinic who had received ≥240 mg/m2 anthracyclines, been in complete remission and off chemotherapy for a minimum of 2 years. * Age \> 9 years of age\* * Parental/caregiver consent and subject assent to enrollment \* Age \> 9 years of age was chosen to avoid the need for general anesthesia or sedation B. Subject Inclusion Criteria * Enrolled in part A of the study, which took place from October 2011 to July 2013. * Parental/caregiver consent and subject assent to enrollment C. Subject Inclusion Criteria * Childhood cancer survivors from the late effect clinic who had received \< 300 mg/m2 anthracyclines, been in complete remission and off chemotherapy for a minimum of 1 year * Age ≥ 9 years of age\* * Parental/caregiver consent and subject assent to enrollment * \* Age \> 9 years of age was chosen to avoid the need for general anesthesia or sedation 5.2 A. Subject Exclusion Criteria * Contraindications to CMRI.\* * Pregnancy\*\* \* Contraindications to CMRI (i.e., magnetically activated implants/devices; cardiac pacemaker or wires; after the patients are scheduled for CMRI, they will be sent our standard pre-MRI paperwork/questionnaire, to determine eligibility to have an MRI) \*\*If a female patient of child bearing age is not sure if they are pregnant or not, as part of the standard CMRI with contrast procedures, a urine pregnancy test will be done. If the result is positive the subject will not be allowed to continue in the study. CMRI with gadolinium may affect a fetus, and also the CMRI results are an integral part of this research study. * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye. B. Subject Exclusion Criteria * Not enrolled in part A of the study * Contraindications to CMRI\* * Pregnancy \*\* * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye * C. Subject Exclusion Criteria * Total Cumulative dose anthracyclines ≥300 mg/m2 * Contraindications to CMRI\* * Pregnancy \*\* * Orbital X-Ray confirmed to have metal in the eye or patient confirmed to have metal in the eye Exclusion Criteria: * Contraindications to CMRI * Relapse of their cancer * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Connecticut Children's Medical Center

    Hartford, Connecticut, 06106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.